The emerging potentials of lncRNA DRAIC in human cancers

Qinfan Yao; Xiuyuan Zhang; Dajin Chen

doi:10.3389/fonc.2022.867670

The emerging potentials of lncRNA DRAIC in human cancers

Front Oncol. 2022 Aug 4:12:867670. doi: 10.3389/fonc.2022.867670. eCollection 2022.

Authors

Qinfan Yao^{1

2

3

4}, Xiuyuan Zhang^{1

2

3

4}, Dajin Chen^{1

2

3

4}

Affiliations

¹ Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
² Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China.
³ National Key Clinical Department of Kidney Diseases, Institute of Nephrology, Zhejiang University, Hangzhou, China.
⁴ Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China.

Abstract

Long non-coding RNA (lncRNA) is a subtype of noncoding RNA that has more than 200 nucleotides. Numerous studies have confirmed that lncRNA is relevant during multiple biological processes through the regulation of various genes, thus affecting disease progression. The lncRNA DRAIC, a newly discovered lncRNA, has been found to be abnormally expressed in a variety of diseases, particularly cancer. Indeed, the dysregulation of DRAIC expression is closely related to clinicopathological features. It was also reported that DRAIC is key to biological functions such as cell proliferation, autophagy, migration, and invasion. Furthermore, DRAIC is of great clinical significance in human disease. In this review, we discuss the expression signature, clinical characteristics, biological functions, relevant mechanisms, and potential clinical applications of DRAIC in several human diseases.

Keywords: DRAIC; application; biological function; lncRNA; mechanism.

Publication types

Review